https://www.patsnap.com/resources/blog/rd-blog/caprolactam-and-nylon-6-intermediate-production-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Chemical Process Routes
Caprolactam and Nylon 6 Intermediate Production Patents
  • Concentrated at the top. The five most active assignees together hold 398 of 691 records in scope (57.6%), and the ten most active hold 519 (75.1%) — a field with little room left for a generic process claim.
  • Filing has plateaued, not accelerated. Activity rose to a peak of 19 records in 2021, sat at 18 by the 2022 midpoint, and has not broken out since — this is a mature route, not an emerging one.
  • Claim density sits almost entirely in two subclasses. C07D heterocyclic chemistry (73.7% of records) and B01J catalysis (37.0%) carry the bulk of the art; separation and nitrogen-byproduct classes are comparatively open.
Get a prior-art report on your approach
691
Published Records
58%
Top-5 Share of All Records
-63%
3-Yr Growth (lag-adjusted)
CN
Leading Jurisdiction
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview

What this landscape covers

This dataset tracks patent activity in caprolactam production and nylon 6 intermediate synthesis, built around the ammoximation route to cyclohexanone oxime, the Beckmann rearrangement that converts oxime to lactam, and the ammonium sulfate byproduct problem that has shaped process design since the hydroxylamine route era. The scope is defined by IPC classes C07D201, C07C249 and C08G69, filtered to records that name these process steps directly rather than downstream polymer claims.

691 records fall within scope from 2015 through the 2026 data cut-off. Publication lags filing by roughly 18 months, so the 2026 count is necessarily incomplete and should not be read as a drop-off.

Filing activity and technology composition, 2017–2026
  1. 1SUMITOMO CHEM CO LTD206
  2. 2DSM IP ASSETS BV58
  3. 3CHINA PETROLEUM & CHEMICAL CORP55
  4. 4MITSUBISHI CHEM CORP40
  5. 5RES INST OF PETROLEUM PROCESSING SINOPEC39
  6. 6BASF SE36
  7. 7CAP III26
  8. 8SUMITOMO KAGAKU KOGYO KK24
  9. 9VERSALIS SPA19
  10. 10UNIV OF SOUTHAMPTON16
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Caprolactam and Nylon 6 Intermediate Production covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The data

Filing trend and technology composition

Two views of the same 691-record set: how filing volume has moved year over year, and which IPC subclasses carry the claim density.

A flat-to-declining filing curve

Filings rose from 14 in 2017 to a peak of 19 in 2021, then held near that level (18 at the 2022 midpoint) without a further breakout. That pattern is consistent with a process technology where the core routes are settled and filing now clusters around incremental catalyst and purification improvements rather than new process architectures.

A flat-to-declining filing curve05101520142017201820192020192021202220232024202522026Most recent year is partial — publication lag means later filings are not yet visible.

Claim density concentrates in two subclasses

C07D (heterocyclic compounds, covering the lactam ring chemistry) appears in 73.7% of the 691 records, and B01J (catalysis and chemical/physical processes) in 37.0% — together they anchor the oxime-to-lactam conversion and the titanosilicate-catalysed ammoximation step. C07C (acyclic/carbocyclic compounds, 32.0%) and C07B (general organic methods, 16.2%) follow. Separation processes (B01D, 2.7%) and nitrogen-compound byproduct handling (C01C, 1.7%) are the thinnest classes, which is notable given how central the ammonium sulfate byproduct problem is to process economics.

Claim density concentrates in two subclassesC07D · Heterocyclic compounds50973.7%B01J · Chemical/physical processes & …25637.0%C07C · Acyclic & carbocyclic compounds22132.0%C07B · General organic chemistry meth…11216.2%C01B · Non-metallic elements & inorga…527.5%B01F · Mixing & stirring355.1%B01D · Separation processes (filtrati…192.7%C01C · Ammonia, cyanides & nitrogen c…121.7%Other395.6%

Shares are the percentage of the 691 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Caprolactam and Nylon 6 Intermediate Production covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Caprolactam and Nylon 6 Intermediate Production with Eureka

This page is one run against one query. Ask Eureka your own question about caprolactam and nylon 6 intermediate production and every answer comes back with the patent numbers behind it.

Try Eureka
Key Patents

The most-cited prior art in this field

Representative filing
US20120078014A12012-03-29

Method for manufacturing cyclohexanone oxime (US20120078014A1)

SUMITOMO CHEMICAL COMPANY

The filing describes producing cyclohexanone oxime by ammoximation of cyclohexanone with hydrogen peroxide and ammonia over a titanosilicate catalyst, using a silicon-compound solid that had previously served as a Beckmann rearrangement catalyst. The stated aim is stable long-term oxime production rather than a one-off yield improvement.Assignee: Sumitomo Chemical. Filed 2012-03-29.

View full filing
Highest-cited records in scope
#Publication no.Patent titleCitations
1CN1269360Aε-己内酰胺的生产方法59
2CN1332158Aε-己内酰胺的制备方法54
3CN1263091Aε-己内酰胺的制备方法53
4JP1990275850AProduction of epsilon-caprolactam50
5CN102050464A硅分子筛的合成方法47
6CN1600428A一种含MFI结构分子筛催化剂的制备方法42
7JP2000229939AProduction of epsilon-caprolactam39
8US6265574B1Process for producing epsi-caprolactam35
9JP2001072658AProduction of amide compound34
10US6828459B2Method for producing cyclohexanone oxime32

Citation counts favour older records simply by virtue of having had longer to accumulate them — read this as a map of influential prior art, not of current filing activity.

Patent titles are shown in the language they were filed in, not translated, so that each record stays verifiable against the original filing — a translated title will not match in Eureka or in any national register. Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Caprolactam and Nylon 6 Intermediate Production covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the numbers mean for a filing decision

Three read-outs from the concentration, geography and citation data that matter more than the raw counts.

Concentration
57.6% / 75.1%
top 5 / top 10 share of 691 records

Five holders already occupy most of the claim space

With the five most active assignees holding 398 of 691 records and the next five bringing the total to 519, a new entrant filing a broad ammoximation or Beckmann rearrangement process claim is filing into ground already covered by incumbents. Differentiation now has to come from a specific catalyst formulation, byproduct handling step, or purity specification rather than the reaction sequence itself.

Source: assignee ranking, 691 records
Geography
China 154 · EPO 103 · US 96
receiving office counts

Filing strategy skews toward China and Europe

China leads receiving offices with 154 filings, ahead of the EPO at 103 and the US at 96, with Japan at 88, India at 44 and WIPO/PCT filings at 32. That ordering reflects where caprolactam production capacity and nylon 6 fibre manufacturing are concentrated, and it is a reasonable guide to where freedom-to-operate checks matter most.

Source: receiving office counts, all records in scope
Citation signal
Top cite: 59
citations on the leading record

The most-cited prior art is a decade or more old

The highest-cited records in this set date to the earlier caprolactam production era and describe core epsilon-caprolactam manufacturing methods; a molecular sieve synthesis patent also ranks highly, reflecting the catalyst work that underpins ammoximation. High citation counts here signal foundational influence within the searched corpus, not that these are the most relevant filings for a 2026 process design.

Source: most-cited records table
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to caprolactam and nylon 6 intermediate production, with the prior art for and against each one.

Find the white space →
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Caprolactam and Nylon 6 Intermediate Production covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players

Who holds the ground, and where it thins out

The ranked leaders account for three-quarters of all filings between them; beyond that the field opens into a long tail of single- and low-digit filers.

Leader
206 records
leading assignee

One filer well ahead of the field

The top-ranked assignee holds 206 of the 691 records in scope, roughly five times the fifth-place count of 39 and well ahead of the tenth-place count of 16. That gap between first and fifth place is the clearest sign of an incumbent with sustained, multi-generation process patenting rather than a single landmark filing.

Source: assignee ranking
Momentum
0 in latest year
recent-year filings, major assignees

Even the leaders have gone quiet recently

Every one of the assignees with recent-year momentum data — including the field's largest filers — shows zero filings in the latest year. Given the 18-month publication lag this understates true 2026 activity, but it is also consistent with the flat filing trend since 2021: this looks like a period of consolidation around existing claims rather than new filing pushes.

Source: recent-year momentum by assignee
Collaboration
10 pairs
co-assignee relationships

Collaboration is concentrated in a few pairings

Only 10 co-assignee pairs appear in the dataset. The strongest link, 31 shared records, sits between a major Chinese petrochemical group and its own research institute — an internal R&D-to-parent relationship rather than an external partnership. A second pairing at 15 shared records connects an industrial conglomerate with a university research group, suggesting academic collaboration plays a small but real role in catalyst-side innovation.

Source: co-assignee pairs
🔍
Under-claimed branches worth a closer look
Sub-areas where filing density is comparatively thin relative to the core reaction chemistry
Ammonium sulfate byproduct valorisationContinuous Beckmann rearrangement separation trainsNitrogen-compound recovery (C01C-adjacent)Mixing/reactor design for ammoximation (B01F)Purity-for-polymerization specification claims
Rank all filers by momentum →
Recent-year filing momentum by major assignee
AssigneeRecent yearYoY
Sumitomo Chemical Co., Ltd.0
DSM IP Assets B.V.0
China Petroleum & Chemical Corporation (Sinopec)0
Mitsubishi Chemical Corporation0
BASF SE0
Sumitomo Chemical Industry Co., Ltd.0
Sinopec Research Institute of Petroleum Processing0
Honeywell International Inc.0
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Caprolactam and Nylon 6 Intermediate Production covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's next

Where to take this analysis

The landscape points to where claim space is occupied and where it is not — the next step is testing a specific process or claim against it.

Check freedom-to-operate on a specific route

If a project centres on ammoximation catalyst chemistry or a Beckmann rearrangement variant, run the specific catalyst formulation or process step against the leading assignees' portfolios before committing to a process design.

Explore this topic in Eureka →

Test white space claims before drafting

The thinner classes around byproduct handling and separation are promising but need validation against the full claim text, not just IPC counts, before a first claim is drafted.

Run a white space search in Eureka →
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Caprolactam and Nylon 6 Intermediate Production covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions about this landscape

Answers are grounded in the same dataset. Derived from a Patsnap search on Caprolactam and Nylon 6 Intermediate Production covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Caprolactam and Nylon 6 Intermediate Production in depth with Eureka

Go past this page: query the whole caprolactam and nylon 6 intermediate production corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.